Yassine MarshallTavistock Clinic: Puberty Blocker Trial Halted — What Families Need to Know Now
The UK's medicines regulator MHRA suspended the PATHWAYS clinical trial of puberty blockers in February 2026 over safety concerns, reigniting debate about the Tavistock gender clinic's legacy and what mental health support young people can now access. This development affects thousands of families navigating gender dysphoria and adolescent mental health care across the UK.
What Happened: The PATHWAYS Trial Is on Hold
The MHRA halted the PATHWAYS trial — which was testing puberty blockers under controlled clinical conditions — citing concerns about informed consent procedures and patient safety protocols. This came months after a Freedom of Information request revealed that only 8 formal complaints about care were filed against the Tavistock Gender Identity Development Service (GIDS) over a decade (2012–2022), despite claims by law firm Pogust Goodhead that hundreds of negligence cases were being investigated.
No medical negligence lawsuits were actually filed, according to legal records reviewed in February 2026. The gap between public perception and documented complaints has fuelled fresh scrutiny of how the Tavistock closure decision was made in 2024.
The Cass Review and Its Lasting Impact
The Tavistock clinic formally closed in March 2024, following the interim Cass Review report which recommended replacing the single national service with regional specialist hubs. Dr Hilary Cass concluded that the evidence base for puberty blockers in treating gender dysphoria in under-18s was insufficient to justify routine prescription.
Eight regional hubs now operate across England and Wales. According to NHS England, these new services are designed to offer a broader multi-disciplinary approach including psychology, psychiatry, and endocrinology — rather than the gender-affirming pathway that characterised Tavistock's approach.
What Mental Health Support Is Available Now
The suspension of the PATHWAYS trial means that young people who might have enrolled in the study are left without a clear clinical pathway for puberty-blocking treatment. For families affected, this raises urgent questions.
For young people experiencing gender dysphoria:
- NHS Talking Therapies (formerly IAPT) offers free psychological support for anxiety and depression — conditions often co-occurring with gender dysphoria
- The new regional hubs offer assessment and psychological support, though waiting times remain significant
- CAMHS (Child and Adolescent Mental Health Services) can provide specialist support for young people under 18
Clinical psychologists working in this area stress that a holistic mental health assessment is often the most valuable first step. Many young people presenting with gender dysphoria also experience anxiety, depression, autism spectrum traits, or family conflict — all of which benefit from specialist psychological intervention regardless of any gender-related decision.
Why Independent Clinical Consultation Matters More Than Ever
With the NHS pathway in flux and the PATHWAYS trial suspended, many families are seeking independent psychiatric or psychological assessments. Private consultations can provide:
- A comprehensive mental health evaluation without waiting lists
- An independent second opinion before any irreversible medical intervention
- Support for parents navigating complex conversations with their child
A consultant psychiatrist or clinical psychologist can assess the full picture of a young person's mental health needs and offer evidence-based recommendations. This is particularly important given that some young people who received puberty blockers at Tavistock have since reported feeling rushed through the process, according to accounts published in The Times in early 2025.
The Legal Angle: Parents' Rights and Informed Consent
The Tavistock controversy has also raised serious questions about informed consent — particularly for under-16s. Under English law, Gillick competence allows a minor to consent to medical treatment if they are deemed capable of fully understanding the implications.
However, the suspension of the PATHWAYS trial suggests that even regulators are uncertain whether sufficient information was being given to participants. For parents, this reinforces the importance of seeking independent legal advice if they feel their child was treated without proper consent procedures.
Looking Ahead: What the Evidence Says
The debate about puberty blockers is not settled. A 2024 systematic review by NHS England found limited high-quality evidence for either the benefits or harms of puberty suppression in adolescents. The MHRA's decision to pause the trial reflects this uncertainty.
Families, clinicians, and policymakers are increasingly calling for better-designed research that follows young people over years, not just during treatment. Until that evidence exists, clinical psychologists and child psychiatrists remain the most important resource for families seeking guidance.
If you are supporting a young person with gender dysphoria or complex mental health needs, a consultation with a qualified clinical psychologist or psychiatrist can help you understand the options and make informed decisions. ExpertZoom connects families with experienced mental health professionals across the UK.
This article provides general information and does not constitute medical or legal advice. If you have concerns about a young person's mental health, seek guidance from a registered healthcare professional. For NHS guidance on gender services, visit NHS England.
